Many of our findings could be explained by the effects of treatment, such as the reduction in Granzyme A. Third, as this study is cross‐sectional and includes participants with established MS, it is challenging to deconvolve the impact of treatment, disease duration, disease stage at the time of sampling, and other time‐varying parameters. The gene discussed is GZMA; the disease is myeloid sarcoma.